Encellin Announces Interim Clinical Results Showing First-in-Human Non-Fibrotic Engraftment and Viable Encapsulated Human Islets in Subjects with Type 1 Diabetes

Encellin, a biotechnology company pioneering Encapsulated Cell Replacement Therapy (ENCRT), today announced interim clinical ...

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Dia…

NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative ...
Longview News-Journal

Orsini Selected as the Exclusive Specialty Pharmacy for Cell Therapy ENCELTO™

ELK GROVE VILLAGE, Ill., April 1, 2025 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, has been selected by Neurotech Pharmaceuticals, Inc., as the exclusive specialty pharmacy ...
Healthline

Understanding the Potential of Stem Cell Therapy for Diabetes Type 2

Stem cell therapy is an emerging treatment for type 2 diabetes. Although it’s not yet FDA-approved in the United States, it is a rapidly expanding and promising field of research. Stem cells are ...